Neuronetics Inc. (NRC)
XFRA 
Summary
NRC Chart
Neuronetics: Top Line Growth, Low Valuation, But Gross Margin Struggles
Neuronetics is revisited following prior coverage in March 2026. The article focuses on STIM's recent developments and their impact on the investment thesis. Key topics include operational progress, financial performance, and forward outlook for STIM.
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.21 per share a year ago.
Neuronetics Inc. (NRC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Neuronetics Inc. ever had a stock split?
Neuronetics Inc. Profile
| Professional Services Industry | Industrials Sector | Daniel L. Reuvers CEO | XFRA Exchange | 64131A105 CUSIP |
| US Country | 658 Employees | - Last Dividend | - Last Split | 28 Jun 2018 IPO Date |
Overview
Neuronetics, Inc. is a pioneer in the medical technology industry, focusing on the development and marketing of innovative solutions for patients suffering from neurohealth disorders. Established in 2001 and based in Malvern, Pennsylvania, the company has made significant strides in offering advanced therapeutic options for individuals diagnosed with major depressive disorder, primarily in the United States and internationally. Neuronetics stands out for its dedication to non-invasive, office-based treatments that aim to improve the quality of life for patients struggling with mental health conditions without the need for systemic medications or invasive procedures.
Products and Services
NeuroStar Advanced Therapy System
This flagship product from Neuronetics represents a groundbreaking approach to treating adult patients with major depressive disorder. The NeuroStar Advanced Therapy System utilizes transcranial magnetic stimulation (TMS) technology to produce a pulsed, MRI-strength magnetic field. This field induces electrical currents in specific areas of the brain associated with mood regulation, thereby stimulating these regions to alleviate depressive symptoms. The system is designed for non-invasive and non-systemic treatment, making it an appealing option for patients seeking alternatives to traditional antidepressant medications or those who have not responded well to other therapies. Neuronetics markets this innovative therapy through a dedicated sales and customer support team, focusing on psychiatrists as the primary channel for distribution.
